chlorferron: metabolite of coumaphos
ID Source | ID |
---|---|
PubMed CID | 5355079 |
CHEMBL ID | 589883 |
CHEBI ID | 38620 |
SCHEMBL ID | 1024770 |
MeSH ID | M0307320 |
Synonym |
---|
nsc 44204 |
unii-evi89ha9v3 |
evi89ha9v3 , |
nsc 24924 |
einecs 228-217-8 |
AN-829/40891487 |
nsc44204 |
nsc-44204 |
nsc24924 |
3-chloro-4-methyl-7-hydroxycoumarin |
6174-86-3 |
chlorferone |
7-hydroxy-4-methyl-3-chlorocoumarin |
nsc-24924 |
2h-1-benzopyran-2-one, 3-chloro-7-hydroxy-4-methyl- |
coumarin, 3-chloro-7-hydroxy-4-methyl- |
3-chloro-7-hydroxy-4-methyl-2h-1-benzopyran-2-one |
3-chloro-7-hydroxy-4-methyl-2-benzopyrone |
chlorferron |
CHEBI:38620 , |
OPREA1_070479 |
3-chloro-7-hydroxy-4-methyl-chromen-2-one |
3-chloro-7-hydroxy-4-methyl-2h-chromen-2-one |
3-chloro-7-hydroxy-4-methylcoumarin, 97% |
AKOS000274050 |
CHEMBL589883 , |
3-chloro-7-hydroxy-4-methylchromen-2-one |
inchi=1/c10h7clo3/c1-5-7-3-2-6(12)4-8(7)14-10(13)9(5)11/h2-4,12h,1h3 |
odzhldrqczxqfq-uhfffaoysa- |
3-chloro-4-methyl-7-hydroxy-2h-2-chromenone |
bdbm50305318 |
A833402 |
3-chloro-7-hydroxy-4-methyl coumarin |
AM806572 |
FT-0615445 |
3-chloro-7-hydroxy-4-methylcoumarin |
3-chloro-4-methylumbelliferone |
umbelliferone, 3-chloro-4-methyl- |
SCHEMBL1024770 |
STL477589 |
3-chloro-4-methyl-7-hydroxy coumarin |
tox21_303840 |
dtxcid8031314 |
NCGC00357111-01 |
dtxsid8052724 , |
cas-6174-86-3 |
3-chloro-7-hydroxy-4-methyl-2h-chromen-2-one # |
3-chloro-7-hydroxy-4-methylcoumarin, analytical standard |
coumaphos alcohol metabolite |
mfcd00006851 |
chlorferon |
AS-50125 |
Q27117921 |
C3098 |
BCP31695 |
chlorferone;3-chloro-7-hydroxy-4-methyl-2h-chromen-2-one pound>>3-chloro-7-hydroxy-4-methylcoumarin |
SB40436 |
O10991 |
EN300-21484 |
Z104499616 |
Class | Description |
---|---|
organochlorine compound | An organochlorine compound is a compound containing at least one carbon-chlorine bond. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
acetylcholinesterase | Homo sapiens (human) | Potency | 53.2770 | 0.0025 | 41.7960 | 15,848.9004 | AID1347395; AID1347398 |
hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 42.8197 | 3.1890 | 29.8841 | 59.4836 | AID1224846; AID1224894 |
SMAD family member 2 | Homo sapiens (human) | Potency | 42.8763 | 0.1737 | 34.3047 | 61.8120 | AID1346859; AID1346924; AID1347035 |
SMAD family member 3 | Homo sapiens (human) | Potency | 42.8763 | 0.1737 | 34.3047 | 61.8120 | AID1346859; AID1346924; AID1347035 |
GLI family zinc finger 3 | Homo sapiens (human) | Potency | 32.5071 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
AR protein | Homo sapiens (human) | Potency | 26.5446 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID1259381 |
estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 44.6097 | 0.0006 | 57.9133 | 22,387.1992 | AID1259377; AID1259378; AID1259394 |
nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 55.5588 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839; AID1224893 |
progesterone receptor | Homo sapiens (human) | Potency | 36.7466 | 0.0004 | 17.9460 | 75.1148 | AID1346784; AID1346795; AID1347036 |
retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 25.5765 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531 |
estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 27.3395 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224848; AID1224849; AID1259403 |
pregnane X nuclear receptor | Homo sapiens (human) | Potency | 68.5896 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 51.5202 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244; AID1259248 |
v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 36.2918 | 0.0578 | 21.1097 | 61.2679 | AID1159526; AID1159528 |
Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 126.7930 | 0.0391 | 47.5451 | 146.8240 | AID1224845 |
Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 48.5577 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 48.5577 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Testosterone 17-beta-dehydrogenase 3 | Homo sapiens (human) | IC50 (µMol) | 0.1000 | 0.0026 | 1.7646 | 9.3000 | AID452459 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
androgen biosynthetic process | Testosterone 17-beta-dehydrogenase 3 | Homo sapiens (human) |
male genitalia development | Testosterone 17-beta-dehydrogenase 3 | Homo sapiens (human) |
testosterone biosynthetic process | Testosterone 17-beta-dehydrogenase 3 | Homo sapiens (human) |
steroid biosynthetic process | Testosterone 17-beta-dehydrogenase 3 | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
estradiol 17-beta-dehydrogenase [NAD(P)] activity | Testosterone 17-beta-dehydrogenase 3 | Homo sapiens (human) |
testosterone dehydrogenase [NAD(P)] activity | Testosterone 17-beta-dehydrogenase 3 | Homo sapiens (human) |
testosterone 17-beta-dehydrogenase (NADP+) activity | Testosterone 17-beta-dehydrogenase 3 | Homo sapiens (human) |
17-beta-hydroxysteroid dehydrogenase (NADP+) activity | Testosterone 17-beta-dehydrogenase 3 | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
plasma membrane | Glutamate receptor 2 | Rattus norvegicus (Norway rat) |
endoplasmic reticulum | Testosterone 17-beta-dehydrogenase 3 | Homo sapiens (human) |
endoplasmic reticulum membrane | Testosterone 17-beta-dehydrogenase 3 | Homo sapiens (human) |
intracellular membrane-bounded organelle | Testosterone 17-beta-dehydrogenase 3 | Homo sapiens (human) |
endoplasmic reticulum | Testosterone 17-beta-dehydrogenase 3 | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID456202 | Inhibition of rat intestinal alpha-glucosidase at 100 ug/mL after 5 mins by spectrophotometry | 2010 | Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1 | alpha-Glucosidase inhibitory antihyperglycemic activity of substituted chromenone derivatives. |
AID452459 | Inhibition of human 17beta-HSD3 expressed in HeLa cells | 2010 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1 | Coumarins as novel 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for potential treatment of prostate cancer. |
AID456203 | Inhibition of rat intestinal alpha-glucosidase after 5 mins by spectrophotometry | 2010 | Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1 | alpha-Glucosidase inhibitory antihyperglycemic activity of substituted chromenone derivatives. |
AID456201 | Antioxidant activity assessed as DPPH radical scavenging activity at 25 ug/mL after 30 mins by spectrophotometry | 2010 | Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1 | alpha-Glucosidase inhibitory antihyperglycemic activity of substituted chromenone derivatives. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 3 (21.43) | 18.7374 |
1990's | 1 (7.14) | 18.2507 |
2000's | 4 (28.57) | 29.6817 |
2010's | 5 (35.71) | 24.3611 |
2020's | 1 (7.14) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.58) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 14 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |